Ortoma Q4’24: Higher product sales than expected - Redeye

Redeye provides a short comment on Ortoma’s Q4 report this morning. There are several essential steps in the quarter. Firstly, the total net sales figure came below what we expected, but its composition is positive as the sales from the De Puy agreement are considerably higher than we expected. The milestones were communicated during the quarter, thus lower than we had expected. The full-year EBITDA is positive, and with upcoming expected approvals in the US and EU, milestone payments should arrive during 2025e. We will adjust for not-yet-arrived milestones and some changes to estimates in the H1 2025e as more of the announced orders arrived in the books earlier than expected. The current Base case is SEK 20 per share, and we do not expect this to change materially.

Länk till analysen i sin helhet: https://www.redeye.se/research/1084193/ortoma-q424-higher-product-sales-than-expected?utm_source=finwire&utm_medium=RSS